[go: up one dir, main page]

GB202209196D0 - Bi-specific antigen binding molecules - Google Patents

Bi-specific antigen binding molecules

Info

Publication number
GB202209196D0
GB202209196D0 GBGB2209196.1A GB202209196A GB202209196D0 GB 202209196 D0 GB202209196 D0 GB 202209196D0 GB 202209196 A GB202209196 A GB 202209196A GB 202209196 D0 GB202209196 D0 GB 202209196D0
Authority
GB
United Kingdom
Prior art keywords
antigen binding
binding molecules
specific antigen
molecules
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2209196.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Discovery Ltd
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Priority to GBGB2209196.1A priority Critical patent/GB202209196D0/en
Publication of GB202209196D0 publication Critical patent/GB202209196D0/en
Priority to PCT/EP2023/067045 priority patent/WO2023247731A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
GBGB2209196.1A 2022-06-22 2022-06-22 Bi-specific antigen binding molecules Ceased GB202209196D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2209196.1A GB202209196D0 (en) 2022-06-22 2022-06-22 Bi-specific antigen binding molecules
PCT/EP2023/067045 WO2023247731A1 (en) 2022-06-22 2023-06-22 Ror1/ptk7 bi-specific antigen binding molecules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2209196.1A GB202209196D0 (en) 2022-06-22 2022-06-22 Bi-specific antigen binding molecules

Publications (1)

Publication Number Publication Date
GB202209196D0 true GB202209196D0 (en) 2022-08-10

Family

ID=82705371

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2209196.1A Ceased GB202209196D0 (en) 2022-06-22 2022-06-22 Bi-specific antigen binding molecules

Country Status (2)

Country Link
GB (1) GB202209196D0 (en)
WO (1) WO2023247731A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067730A2 (en) * 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules

Also Published As

Publication number Publication date
WO2023247731A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
GB202020154D0 (en) ROR1-specific variant antigen binding molecules
IL275483A (en) Bi-specific antigen binding molecules
EP4048701A4 (en) Anti-cd40 binding molecules and bi-specific antibodies comprising such
IL316848A (en) Antigen binding molecules targeting sars-cov-2
IL284926A (en) Cd3-specific binding molecules
IL299630A (en) Antigen binding molecules targeting sars-cov-2
IL299631A (en) Antigen binding molecules targeting sars-cov-2
GB202006629D0 (en) Specific binding molecules
EP4320165A4 (en) Antigen binding proteins that bind ror1
IL290371A (en) Novel antigen binding molecule formats
IL304745A (en) Complement c3 antigen binding proteins
SG11202109535SA (en) Cd3 binding molecules
IL308394A (en) Bispecific binding molecule
GB202306345D0 (en) Binding molecules
GB202010329D0 (en) Specific binding molecules
IL317632A (en) Ror1/egfr bi-specific antigen binding molecules
GB202209196D0 (en) Bi-specific antigen binding molecules
GB202215636D0 (en) Bi-specific variant antigen binding molecules
GB202209197D0 (en) Bi-specific variant antigen binding molecules
GB202305455D0 (en) Antigen binding molecules
GB202219467D0 (en) Antigen binding molecules
AU2021377213A9 (en) Bi-specific antibodies comprising anti-cd137 binding molecules
GB202000814D0 (en) Antigen binding molecules that bind bdca-2
GB201911188D0 (en) Antigen binding molecules that bind BDCA-2
HK40094756A (en) Ror1-specific variant antigen binding molecules

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)